Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VALO-2: A Multicenter, Phase 3b, Open-Label Treatment Extension Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

NCT04520750 is registered in ClinicalTrials.gov with Palvella Therapeutics, Inc. as lead sponsor.

NCT NCT04520750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04520750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VALO-2: A Multicenter, Phase 3b, Open-Label Treatment Extension Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Lead sponsor
Palvella Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2020
Completion date
December 15, 2022
Enrollment
36 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pachyonychia congenita